Expert panel endorse individualized beta-lactam dosing for acutely ill patients - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Expert panel endorse individualized beta-lactam dosing for acutely ill patients

International guidance supports concentration-guided dosing for selected acutely ill patients, with clinical cure showing the clearest benefit.

  • By

  • Doug Brunk

  • August 17, 2026

  • 7 min

Share

Clinical Report: Expert panel endorse individualized beta-lactam dosing

Overview

An international expert panel has conditionally endorsed individualized beta-lactam dosing for critically ill patients. The panel's guidance highlights the variability in drug levels among patients and the potential benefits of tailoring dosing based on measured drug concentrations.

Background

Individualized dosing of beta-lactam antibiotics is increasingly recognized as a critical approach in managing critically ill patients, particularly due to the significant interpatient variability in drug pharmacokinetics. Standard dosing methods may not adequately address the unique needs of these patients.

Data Highlights

Study TypeFindings
Randomized TrialsIndividualized dosing linked to improved clinical cure rates.
Observational StudiesLower mortality associated with individualized dosing, but not statistically significant.

Key Findings

  • Drug levels can vary by 10- to 30-fold among patients.
  • Individualized dosing is recommended for patients with altered kidney function and other specific conditions.
  • Evidence for mortality benefits remains inconclusive.
  • Safety concerns exist regarding very high beta-lactam levels and potential side effects.

Clinical Implications

Monitoring drug levels may enhance treatment efficacy and safety.

Conclusion

The endorsement of individualized beta-lactam dosing represents a shift towards precision medicine in critical care.

Related Resources & Content

  1. Barreto E.F., Pharmacotherapy, 2023 -- Expert panel endorse individualized beta-lactam dosing for acutely ill patients
  2. Intensive Care Medicine — Tailoring Antibiotic Dosage for ICU Patients: Importance of Timing, Targets, and Model Selection
  3. Critical Care (Springer) — Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review
  4. Intensive Care Medicine — Precision Dosing of Beta-Lactam Antibiotics and Ciprofloxacin in Critically Ill Patients: Results from a Multicenter Randomized Clinical Trial
  5. Intensive Care Medicine — Addressing Study Design Issues and Proposing Further Analysis of Therapeutic Drug Monitoring for Piperacillin/Tazobactam Treatment in Sepsis Patients: Author's Response
  6. Surviving Sepsis Campaign Adult Guidelines | SCCM
  7. ACCP Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients
  8. Continuous versus intermittent beta-lactam antibiotic infusions in critically ill patients: The UK cohort of the BLING III trial - PubMed
  9. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial | Trials | JAMA | JAMA Network
  10. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis | Infectious Diseases | JAMA | JAMA Network
  11. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial | Intensive Care Medicine | Springer Nature Link
  12. Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity - PMC
  13. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients | Clinical Infectious Diseases | Oxford Academic

Original Source(s)

Expert panel endorse individualized beta-lactam dosing for acutely ill patients

  • by Doug Brunk

  • August 17, 2026

Related Content

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

Rapid AST Speeds Care, Not Outcomes

Faster antibiotic optimization may still support use of rapid testing, particularly when paired with stewardship.